Cagrilintide represents a significant advancement in metabolic research tools. As a long-acting amylin analogue, it targets a satiety pathway that operates independently of — and complementary to — the GLP-1 system. This distinction makes it invaluable for researchers exploring multi-receptor approaches to metabolic regulation.

Native amylin is co-secreted with insulin from pancreatic beta cells after meals. It acts centrally to reduce appetite, slow gastric emptying, and suppress glucagon release. Cagrilintide's acylated structure extends these effects over approximately 160–195 hours — enabling weekly research protocols while maintaining consistent receptor activation.

What makes Cagrilintide particularly compelling is its synergistic potential with GLP-1 agonists. By targeting distinct but complementary pathways, combination approaches may achieve metabolic effects that exceed either mechanism alone. This has made Cagrilintide central to next-generation metabolic combination research.

For research teams investigating satiety mechanisms, glucose homeostasis, or multi-pathway metabolic interventions, Cagrilintide provides access to the amylin system with the pharmacokinetic profile needed for sustained, practical research protocols.

For research use only. Not for human consumption.